Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in <i>De Novo</i> Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial
10.1111/ajt.12955
Saved in:
Main Authors: | Budde, K, Bunnapradist, S, Grinyo, JM, Ciechanowski, K, Denny, JE, Silva, HT, Rostaing, L, on behalf of the Envarsus study group |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
Wiley
2022
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/229294 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Novel Once-Daily Extended-Release Tacrolimus(LCPT) Versus Twice-Daily Tacrolimus in De NovoKidney Transplants: One-Year Results of Phase III,Double-Blind, Randomized Trial
by: Budde, K, et al.
Published: (2022) -
Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial
by: Lionel Rostaing, et al.
Published: (2022) -
Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies
by: Somratai Vadcharavivad, et al.
Published: (2020) -
Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study
by: Sayamon Sukkha, et al.
Published: (2018) -
The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients
by: Sayamon Sukkha, et al.
Published: (2020)